BOLT (Bolt Biotherapeutics) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


BOLT Bolt Biotherapeutics Inc BOLT
55 GF Score
Price $4.13
GF Value $9.05
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Bolt Biotherapeutics Long-Term Debt?

Bolt Biotherapeutics BOLT +1.50% 55 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates BOLT with a GF Score™ of 55/100 and a GF Value™ of $9.05 (Possible Value Trap). The stock has 4 warning signs investors should review.

Bolt Biotherapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Bolt Biotherapeutics  (NAS:BOLT) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Bolt Biotherapeutics Long-Term Debt Related Terms

Bolt Biotherapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Bolt Biotherapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bolt Biotherapeutics Long-Term Debt Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Bolt Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOLT
55GF Score
Bolt Biotherapeutics Inc BOLT
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Bolt Biotherapeutics (BOLT) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Bolt Biotherapeutics' Long-Term Debt too high?
Bolt Biotherapeutics' current Long-Term Debt is $0.00 Mil. Overall, Bolt Biotherapeutics has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bolt Biotherapeutics' Long-Term Debt compare to AIM and ERNA?
Bolt Biotherapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Bolt Biotherapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bolt Biotherapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bolt Biotherapeutics (BOLT) is currently considered Possible Value Trap. The stock's GF Value™ is $9.05, compared to a current price of $4.13 — trading 54.4% below its estimated fair value. The current Long-Term Debt is $0.00 Mil. Bolt Biotherapeutics' overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Bolt Biotherapeutics (BOLT), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bolt Biotherapeutics (BOLT) Overvalued in 2026?

Based on GuruFocus' analysis, Bolt Biotherapeutics stock appears to be undervalued. The current stock price of $4.13 is trading 54.4% below its estimated GF Value™ of $9.05. GuruFocus considers Bolt Biotherapeutics to be Possible Value Trap.

Key valuation signals for BOLT:

  • Long-Term Debt: $0.00 Mil
  • GF Value™: $9.05 vs. price of $4.13 (54.4% below fair value)
  • GF Score™: 55/100 with 4 warning signs

No single metric tells the full story. See the BOLT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bolt Biotherapeutics Business Description

Address 900 Chesapeake Drive, Redwood City, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
55GF Score

Get the complete analysis for BOLT

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.13
Price
$9.05
GF Value